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Because the efﬁcacy of donor lymphocyte infusion (DLI) for acute myeloid leukemia (AML) relapse after
allogeneic hematopoietic stem cell transplantation (HSCT) remains uncertain, especially in the Asian popu-
lation, a nationwide registry study was retrospectively performed by the Adult AML Working Group of the
Japan Society for Hematopoietic Cell Transplantation to identify the factors affecting the patient survival after
DLI. Among 143 adult AML patients who received DLI for the treatment of ﬁrst hematological relapse after
HSCT, the overall survival rates at 1 year, 2 years, and 5 years were 32%  4%, 17%  3%, and 7%  3%,
respectively. Complete remission (CR) at the time of DLI, which was obtained in 8% of the patients, was the
strongest predictive factor for survival after DLI. Therefore, long-term survival after DLI was achieved almost
exclusively in patients who successfully achieved a CR before DLI, indicating the limited efﬁcacy of DLI in a
minority of patients.
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Relapse remains a major obstacle to the survival of pa-
tients with acute myelogenous leukemia (AML) after allo-
geneic hematopoietic stem cell transplantation (HSCT),
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14.07.010allogeneic HSCT is unclear, donor lymphocyte infusion (DLI)
is 1 of the most common interventions used for AML relapse,
with the expectation of inducing a graft-versus-leukemia
(GVL) effect [2-4]. However, treatment success for AML
relapse is limited, with overall survival (OS) rates of 10% to
20% at 3 years in previous studies [2-8]. To predict the efﬁ-
cacy of DLI in advance may lead to the selection of different
treatments, including second HSCT, for patients predicted to
be unresponsive to DLI. Until now, large-scale studies to
analyze the risk factors for the success of DLI have been
scarce, especially in the Asian population. The aim of thisTransplantation.
Table 1
Characteristics of the Adult Patients who received DLI for the Treatment of
Their First Hematological Relapse after HSCT for AML
No. of patients 143
Age at relapse, median (range), yr 49 (16-67)
Cytogenetics
Good 20 (14)
Intermediate 81 (57)
Poor 42 (29)
Follow-up of survivors after DLI, median (range), d 459 (73-4377)
Interval from relapse to DLI, median (range), d 37 (0-841)
Extramedullary relapse
No 131 (92)
Yes 12 (8)
Acute GVHD present at relapse
No 69 (48)
Yes 71 (50)
Data missing 3 (2)
Chronic GVHD present at relapse
No 95 (66)
Yes 28 (20)
Not evaluated or missing 20 (14)
Acute or chronic GVHD present at relapse
No 62 (43)
Yes 79 (55)
Data missing 2 (1)
Chemotherapy before DLI
No 21 (14)
Yes 55 (38)
Data missing 67 (47)
Status at DLI
Active disease or aplasia 132 (92)
Complete remission 11 (8)
Transfusions, n
1 109 (76)
2 22 (15)
 3 12 (8)
Acute GVHD after DLI
Yes 26 (18)
No 117 (82)
Cause of death
Infection 11 (9)
Interstitial pneumonia 4 (3)
GVHD 2 (2)
Hemorrhage 6 (5)
Organ failure 11 (9)
Persistent or relapsed leukemia 86 (71)
Data missing 1 (1)
Data presented are n (%), unless otherwise indicated.
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efﬁcacy of DLI for adult patients with a ﬁrst hematological
relapse after allogeneic HSCT, using national registry-based
data of the Transplant Registry Uniﬁed Management Pro-
gram (TRUMP) in Japan.
PATIENTS AND METHODS
Data Collection
The data for 14,286 Japanese patients with AML who underwent HSCT
were obtained from the TRUMP in Japan [9]. Data regarding white blood cell
count at diagnosis, blast count and chimerism at relapse, and cell dose of DLI
were not available for this cohort. Inclusion was based on the following
criteria: ﬁrst allogeneic, bone marrow (BM) or peripheral blood stem cell
(PBSC) HSCT between 1991 and 2011, age  16 years at transplantation, and
DLI recipients after the ﬁrst hematological relapse after HSCT without
precedence of a second transplantation. Patients with myelodysplastic
syndrome, secondary AML frommyelodysplastic syndrome, or a subsequent
relapse of AML were excluded. Patients never in remission at trans-
plantation were excluded. A total of 143 patients met the criteria for study
inclusion. The study design was approved by the TRUMP data management
committee of the Japan Society for Hematopoietic Cell Transplantation and
the institutional review board of Kanazawa University Hospital, where this
study was organized.
Deﬁnitions
DLIwas deﬁned as transfusion of unstimulated lymphocyte concentrates,
collected from the original stem cell donor as buffy coat preparations. Ac-
cording to a previous study [3], the transfusion of unmanipulated mobilized
PBSC concentrates was also deﬁned as DLI, if no prophylactic immunosup-
pressive medication was given, whereas the infusion of donor PBSC or BM
after conditioning the patient with prophylactic immunosuppression for
graft-versus-host disease (GVHD) prevention was deﬁned as a second HSCT.
The physicians who performed transplantation at each center diagnosed and
graded acute and chronic GVHD according to traditional criteria [10,11].
Complete remission (CR) was deﬁned by normal values for the absolute
neutrophil count (>1000/mL) and platelet count (>100,000/mL), indepen-
dence from red cell transfusion, and absence of signs of leukemia without
ongoing antileukemic therapy, based on the revised recommendations of the
international working group [12]. The classiﬁcation of conditioning regimens
as towhether theyweremyeloablative or reduced-intensitywas based on the
report by the Center for International Blood andMarrow Transplant Research
[13]. Cytogenetic subgroups were classiﬁed according to the Southwest
Oncology Group/Eastern Cooperative Oncology Group criteria [14].
Endpoints
The primary study endpoint was to identify the factors affecting the OS
after DLI.
Statistical Analysis
All statistical analyses were performed with the EZR software package
(Saitama Medical Center, Jichi Medical University), a graphical user interface
for R (The R Foundation for Statistical Computing, version 2.13.0) [15].
Variables included the recipient’s age at time of transplantation, sex,
pretransplantation cytomegalovirus serostatus, disease characteristics
(FrencheAmericaneBritish classiﬁcation [FAB] and cytogenetics), donor
characteristics (age, sex, ABO and HLA compatibility), transplantation
characteristics (year of transplantation, disease status at transplantation,
conditioning, source of stem cells, acute GVHD, and/or chronic GVHD before
DLI), and relapse and DLI characteristics (interval from transplantation to
relapse, interval from relapse to DLI, chemotherapy before DLI, disease
status at DLI, and acute GVHD after DLI). The median was used as the cutoff
point for continuous variables. The chi-square test and the Mann-Whitney
U test were used to compare data between 2 groups. The probability of OS
was calculated using the Kaplan-Meier method and compared using the
log-rank test. The probabilities of acute and chronic GVHD were analyzed
using a cumulative incidence analysis [16], while considering death without
acute GVHD and death without chronic GVHD as respective competing risks.
All factors found to be signiﬁcant in the univariate analyses (P  .10) were
included in multivariate Cox hazard models. For both the univariate and
multivariate analyses, P values were 2-sided and the outcomes were
considered to be signiﬁcant for values of P  .05.
RESULTS
Patient Characteristics
A total 143 patients with AML who received DLI for
treatment of a ﬁrst hematological relapse after allogeneicHSCT were included in the study (Table 1). The median time
interval from HSCT to relapse was 149 days (range, 28 to
2153) and from relapse to DLI was 37 days (range, 0 to 841).
Only 8% of patients had obtained CR at the time of DLI. One
single infusion of DLI was given to 76% of patients, and the
remaining patients received 2 or more infusions.
OS after DLI
In the 143 relapse patients who received DLI, the 1-year,
2-year, and 5-year OS rates from DLI were 32%  4%,
17% 3%, and 7% 3%, respectively. Among the 143 patients,
121 patients (85%) died after DLI, and themain cause of death
was persistent or relapsed leukemia in 86 patients (71%),
infections in 11 (9%), organ failure in 11 (9%), hemorrhage in 6
(5%), interstitial pneumonia in 4 (3%), and GVHD in 2 patients
(2%). The median follow-up of the remaining 22 survivors
after DLI was 459 days (range, 73 to 4377).
The factors signiﬁcantly associated with a shorter OS after
DLI based on the univariate analysis included male sex, sex
match of the donor and recipient in contrast to a male donor
for a female recipient, HLA mismatch of the donor and
recipient, a related PBSC recipient at HSCT compared with a
Table 2
Results of Univariate Analysis of the Risk Factors for Survival after DLI
Characteristic OS at
One Year
OS at
Two Years
P Value
% SE % SE
Overall 32% 4% 17% 3%
Patient age, yr
<49 24% 5% 17% 5%
49 21% 5% 9% 4% .25
Patient sex
Female 29% 6% 15% 5%
Male 18% 4% 12% 4% .02
Donor age, yr
<37 25% 6% 15% 5%
37 19% 5% 12% 5% .47
Donor sex
Male 24% 5% 14% 4%
Female 20% 6% 12% 5% .40
Sex matching
Male donor to female recipient 35% 8% 21% 7%
Female donor to male recipient 22% 8% 18% 8% .07
Matched 16% 4% 9% 3% .02
ABO matching
Matched 22% 5% 13% 4%
Major mismatched 36% 13% NA NA .16
Minor mismatched 13% 7% 9% 6% .76
Major-minor mismatched 22% 14% NA NA .77
ABO major mismatching
No 20% 4% 12% 3%
Yes 30% 10% NA NA .16
ABO minor mismatching
No 24% 4% 16% 4%
Yes 16% 6% 8% 5% .71
HLA matching
Matched 25% 4% 16% 4%
Mismatched 16% 7% NA NA .05
Type of HLA-matched donor
Related 23% 5% 13% 4%
Unrelated 29% 8% 25% 8% .88
Source of stem cells
Related BM 30% 8% 15% 6%
Related PBSC 17% 5% 10% 4% .03
Unrelated BM 24% 7% 21% 7% .38
Status at transplantation
CR1 or CR2 25% 5% 13% 4%
Advanced 21% 5% 15% 5% .69
Pretransplantation CMV serostatus
CMV positive recipient 26% 4% 15% 4%
CMV negative recipient 10% 7% 0% NA .30
Year of transplantation
<2006 23% 6% 16% 5%
2006 22% 5% NA NA .47
Cytogenetic subgroup
Good 33% 11% 27% 10%
Intermediate 26% 5% 14% 4% .36
Poor 10% 6% NA NA .04
Conditioning for transplantation
Myeloablative 22% 5% 16% 4%
Reduced intensity 23% 6% 10% 5% .78
Interval from transplantation to relapse, mo
<5 15% 4% 7% 3%
5 34% 7% 23% 6% .001
Acute GVHD at time of relapse
No 22% 5% 13% 4%
Yes 23% 5% 15% 5% .74
Chronic GVHD at time of relapse
No 19% 4% 12% 4%
Yes 33% 10% 19% 8% .34
Acute or chronic GVHD at time of relapse
No 22% 5% 12% 4%
Yes 24% 5% 15% 4% .68
Extramedullary relapse
No 28% 7% 18% 6%
Yes 17% 14% NA NA .99
(Continued)
Table 2
(continued)
Characteristic OS at
One Year
OS at
Two Years
P Value
% SE % SE
Interval from relapse to DLI, d
37 32% 6% 19% 5%
<37 12% 4% 9% 4% .003
Chemotherapy before DLI
No 29% 11% NA NA
Yes 26% 7% 21% 6% .41
Status at DLI
CR 100% NA 100% NA
Active disease or aplasia 17% 3% 8% 3% .00001
Acute GVHD after DLI
No 32% 8% 23% 7%
Yes 26% 9% NA NA .89
Second transplantation after relapse
No 22% 4% 15% 4%
Yes 25% 9% 8% 6% .80
NA indicates not available; CMV, cytomegalovirus.
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cytogenetics, a shorter interval (<5 months) from HSCT to
relapse, a shorter interval (<37 days) from relapse to DLI,
active disease or aplasia at the time of DLI, and a single
infusion of DLI (Table 2). Other factors, such as the patient
and donor age, presence of GVHD at relapse, and the devel-
opment of acute GVHD after DLI, did not signiﬁcantly inﬂu-
ence OS after DLI.
A total of 26 patients developed acute GVHD after DLI
(Table 1), with grade I GVHD in 15 patients, grade II in 5,
grade III in 5, and grade IV in 1 patient. Of the 26 patients, 17
(69%), 3 (12%), 2 (8%), and 4 (15%) patients experienced acute
GVHD after 1, 2, 3, and 4 courses of DLI, respectively. Eight
(31%) of the 26 patients achieved disease-free survival after
DLI, with durations ranging from 82 to 2258 days (median,
362 days), whereas 14 (12%) of the 121 patients without
acute GVHD experienced disease-free survival. It may be
noted that 5 (33%) of the 15 patients who developed grade I
acute GVHD after DLI survived without disease over 2 years,
and that 2 of the 26 patients who developed GVHD subse-
quently developed chronic GVHD, and both patients survived
long-term without disease. Three other patients developed
chronic GVHD without experiencing acute GVHD after DLI,
and 2 of these 3 patients survived without disease for over
2 years. These data might suggest the association of GVHD
after DLI with a substantial GVL effect.
The impact of GVHD on OS after DLI was evaluated as a
time-dependent variable. In a multivariate analysis, a shorter
interval from HSCT to relapse (hazard ratio, 1.76; 95% conﬁ-
dence interval, 1.10 to 2.57; P ¼ .02) and active disease or
aplasia at time of DLI (hazard ratio, 9.98; 95% conﬁdence
interval, 2.27 to 43.9; P ¼ .002) remained signiﬁcantly asso-
ciated with a shorter OS (Table 3). The number of DLI in-
fusions was closely linked to the interval from relapse to DLI
and was, therefore, eliminated from the multivariate model.
Disease stage at DLI had a relatively greater impact on OS
after DLI compared with the interval fromHSCT to relapse. In
addition, among the 11 patients who had obtained CR at the
time of DLI, 10 patients showed a longer interval from HSCT
to relapse.
Accordingly, 3 prognostic groups were categorized as
follows: CR at DLI, regardless of the interval from HSCT to
Table 3
Results of Multivariate Analysis of Risk Factors for Survival after DLI
Prognostic Factor P Value Hazard Risk
for OS
95% CI
Female versus male .49 1.24 .68-2.25
Male donor to female recipient
versus female donor to male
recipient
.69 1.20 .50-2.87
Male donor to female recipient
versus sex matched
.36 1.35 .71-2.57
HLA matched versus HLA
mismatched
.19 1.39 .85-2.27
Good cytogenetics versus
intermediate cytogenetics
.21 1.45 .81-2.59
Good cytogenetics versus poor
cytogenetics
.09 1.76 .92-3.39
Interval from transplantation to
relapse, ‡ 5 mo versus <5 mo
.02 1.68 1.10-2.57
Interval from relapse to DLI,  37 d
versus <37 d
.35 1.23 .80-1.90
Disease stage at DLI (complete
remission versus active disease
or aplasia)
.002 9.98 2.27-43.9
The bold results show values with a P  .05.
CI indicates the conﬁdence interval.
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HSCT to relapse but not in CR at DLI (group 2; n ¼ 51), and
others (group 3; n ¼ 81) (Table 4, Figure 1). Among the pa-
tients who received DLI while in CR (group 1), the 2-year OS
was as high as 100%, which was signiﬁcantly better than that
observed in thosewith a longer interval fromHSCT to relapse
without CR at DLI (group 2; 12%, P < .001) and a shorter in-
terval from HSCT to relapse without CR at DLI (group 3; 4%,
P < .001). Of note, no signiﬁcant differences in OS after DLI
were noted between group 2 and group 3 (P ¼ .13). Accord-
ingly, CR at the time of DLI was the strongest factor with a
signiﬁcant impact on OS after DLI.DISCUSSION
Despite advances in decreasing the nonrelapse mortality
(NRM) after allogeneic HSCT [17], there has been little
progress in reducing the incidence of relapse or in improving
the subsequent outcome. The long-term survival rate after
relapse for patients who underwent transplantation with
AML was reported to be 5% [18,19], although salvage therapy,
such as withdrawal of immunosuppression, chemotherapy,
radiotherapy, a second HSCT, and DLI have been attempted.
However, durable remission occasionally develops after DLI
for AML relapse [2-8]. The current nationwide study con-
ﬁrmed that AML patients who successfully achieved CR after
relapse may beneﬁt from DLI. Although the 5-year OS from
relapse was low at 7%, a subset of patients who achieved CR
before DLI had a signiﬁcantly better 5-year OS of 50%, sup-
porting the use of this treatment strategy [2,3] when a CR
is obtained by salvage treatment, such as withdrawal of
immunosuppression and/or salvage chemotherapy, andTable 4
Survival of Adult Patients Receiving DLI for Treatment of First Hematological Relap
Prognostic Group n OS at One Year
% SE
Group 1: CR at DLI 11 100% 0%
Group 2: Interval from transplantation
to relapse,5mo, but not in CR at DLI
51 24% 6%
Group 3: Others 81 14% 4%immediate consolidation with DLI should be recommended
to improve the chance for long-term survival after AML
relapse.
Previous studies have identiﬁed several factors that are
associated with a good prognosis after DLI, including
achievement of hematological remission before DLI, a lower
tumor burden at relapse, female sex, favorable cytogenetics,
remission at the time of DLI, a longer duration of remission
after HSCT, and the absence of acute GVHD after HSCT
[2,3,5,20-22], the most important of which were the tumor
burden at relapse and the duration of remission after HSCT.
The present study supports the importance of disease control
before DLI.
One drawback is that the study was a retrospective reg-
istry analysis, limiting the risk factors that were available for
analysis, including not only the blast count at relapse, but
also the dose of mononuclear cells in the DLI grafts and the
use of granulocyte colonyestimulating factor before har-
vesting the infused lymphocytes.
A second HSCT with or without DLI represents a good
alternative treatment [3] because, at the current moment,
the approaches expected to offer long-term survival for pa-
tients with AML who relapse after HSCT are conﬁned to DLI
and second HSCT. However, a second HSCT after myeloa-
blative conditioning has historically been associated with
poor survival, with higher NRM rates ranging from 25% to
45%. Recent approaches with a second HSCT after a reduced-
intensity conditioning regimen minimized NRM rates to 0 to
30%, but this could be offset by the higher relapse rates after
the second HSCT [1,23]. There have been few reports on
whether DLI was superior to second HSCT, and a comparison
of the efﬁcacy of DLI and second HSCT for AML relapse is
outside the scope of the present study. However, as shown
Table 2, a second HSCT after DLI did not have a signiﬁcant
impact on the OS in patients with AML relapse.
Various modiﬁcations of DLI have been investigated, such
as ex vivo activated DLI and earlier introduction of DLI [24-
26]. A recent report [26] showed that preemptive DLI given
when minimal residual disease (MRD) was detected effec-
tively reverted MRD back to remission in all 16 treated
patients with acute leukemia and offered long-term survival
in 15 of the 16 patients without increasing the risk of GVHD
development. Thus, early detection of potential disease
progression by detecting MRD and subsequently performing
DLI before overt relapsemight be a better way to improve the
success of HSCT for AML.
The major risk of DLI is the development of GVHD, which
occurs in 40% to 80% of patients [20,27,28], placing patients at
risk of signiﬁcant morbidity and mortality. In the present
study, the cumulative incidence of acute GVHD after DLI was
as high as 82%. However, the development of acute GVHD
after DLI did not signiﬁcantly affect the long-term survival
and it only caused 2% of the deaths. The majority of deaths
resulted from original disease, which accounted for 79% of
the deaths.se after HSCT for AML (n ¼ 143) Stratiﬁed according to Prognostic Group
OS at Two Years OS at Five Years P Value
% SE % SE
100% 0% 50% 25%
12% 4% 9% 5% <.001
6% 3% 0% 0% <.001
Figure 1. Survival after DLI according to the prognostic groups. Group 1 had a
CR at DLI, regardless of the interval from HSCT to relapse (n ¼ 11). Group 2 had
a longer interval (5 months) from HSCT to relapse, but was not in CR at DLI
(n ¼ 51). Group 3 included the other patients (n ¼ 81).
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about cases after DLI in the Asian population, several large-
scale studies [2,3,6,7,27,29] that evaluated the efﬁcacy of
DLI for AML relapse after HSCT in non-Asian population have
been reported. The OS rates from DLI in those studies ranged
from 21% to 37%, 14% to 25%, 12% to 20%, and 10% to 15% at 1,
2, 3, and 5 years, respectively; comparable with the OS rates
in the present study for the Asian population, which were
32%, 17%, 10%, and 7% at 1, 2, 3, and 5 years. The European
Group for Blood and Marrow Transplantation Group [3] re-
ported several factors that were associated with better OS,
including remission at the time of DLI, as seen in the present
study, bone marrow blasts less than 35% at relapse, female
sex, and favorable cytogenetics. Therefore, there does not
appear to be any major differences between the Asian and
non-Asian populations in the context of the potent antileu-
kemic effect of DLI for AML.
The nature of a retrospective, registry-based analysis
implicates several limitations. There were missing data on
the type of chemotherapy administered before DLI, no in-
formation about the cell doses and whether the DLI was a
fresh infusion. Unfortunately, the present registry-based data
do not include this information, and to collect such missing
data is out of the scope of the present study. Therefore,
further studies are warranted.
The present cohort does not include patients who
received prophylactic immunosuppression, either after DLI
or unmanipulated PBSC infusion, according to a previous
report [3], to allow us to evaluate the pure GVL effect.
The results of this large retrospective study demonstrate
that the efﬁcacy of DLI is limited for the treatment of AML
relapse after HSCT, and disease control at the time of DLI
is critical for treatment success irrespective of operative
chemotherapy before obtaining remission. However, the
number of patients with CR was quite small (n ¼ 11), and,
therefore, conclusions should be considered with caution.
New strategies to enhance and maintain the GVL effect of
DLI while minimizing GVHD, which includes preemptive/
prophylactic DLI before overt relapse, costimulation withcytokines or dendritic cells, and use of the leukemia-speciﬁc
antibodies, such as gemtuzumab ozogamicin, should be
considered.
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